Truist raises Alnylam’s price target to $535 from $459, maintains Buy rating ahead of Q3 results. Q3 Amvuttra sales estimate increased to $690M. Forward estimates revised higher based on strong early adoption and feedback indicating wider extracardiac manifestations of ATTR-CM. Analyst shares insights in research note.

Unlock TipRanks Premium at 50% off for powerful investing tools and expert analyst insights. Visit TheFly for real-time, market-moving financial news. Explore top stocks recommended by analysts for investment opportunities. Read more on ALNY and find Disclaimer & Disclosure information on TipRanks website.

Read more at Yahoo Finance: Alnylam price target raised to $535 from $459 at Truist